Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet’s Uveitis Not Responding to Conventional Therapy

REFERENCES

• Cunningham ET, Jr., Tugal-Tutkun I, Khairallah M, Okada AA, Bodaghi B, Zierhut M. Behcet uveitis. Ocular Immunology and Inflammation. Feb 2017;25(1):2–6.
   PubMed Web of Science ®Google Scholar
• Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behcet’s disease: from Hippocrates to the third millennium. The British Journal of Ophthalmology. Sep 2003;87(9):1175–1183.
   PubMed Web of Science ®Google Scholar
• Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Therapeutic Advances in Chronic Disease. May 2014;5(3):112–134.
   PubMedGoogle Scholar
• Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet’s syndrome. The Cochrane Database of Systematic Reviews. 2000;10(2):CD001084.
   Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. American Journal of Ophthalmology. Sep 2004;138(3):373–380.
   PubMed Web of Science ®Google Scholar
• Kaçmaz RO, Kempen JH, Newcomb C, et al. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. American Journal of Ophthalmology. Dec 2008;146(6):828–836.
   PubMed Web of Science ®Google Scholar
• Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of Chinese patients with Behçet’s disease. Ophthalmology. Feb 2008;115(2):312–318. e314.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular Behçet disease. Ocular Immunology and Inflammation. Feb 2014;22(1):64–76.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis & Rheumatism. Sep 2010;62(9):2796–2805.
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet’s uveitis refractory to conventional treatments. Ophthalmology. Jul 2010;117(7):1430–1435.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Archives of Ophthalmology. Mar 2011;129(3):288–294.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet. May 05, 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. Apr 1985;92(4):467–471.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. American Journal of Ophthalmology. Sep 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Virgili G, Acosta R, Grover LL, Bentley SA, Giacomelli G. Reading aids for adults with low vision. The Cochrane Database of Systematic Reviews. 2013;10:CD003303.
   Google Scholar
• Ferris FL, 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. American Journal of Ophthalmology. Jul 1982;94(1):91–96.
   PubMed Web of Science ®Google Scholar
• Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. The British Journal of Ophthalmology. Apr 2003;87(4):423–431.
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Seminars in Arthritis and Rheumatism. Apr 2004;33(5):320–335.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. Dec 2006;244(12):1692–1695.
   PubMed Web of Science ®Google Scholar
• Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet’s disease. Ocular Immunology and Inflammation. Dec 2000;8(4):293–301.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. The Israel Medical Association Journal: IMAJ. Nov 2002;4(11 Suppl):928–930.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. American Journal of Ophthalmology. Dec 2008;146(6):837–844. e831.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. The British Journal of Ophthalmology. Mar 2007;91(3):335–339.
   PubMed Web of Science ®Google Scholar
• Hou S, Kijlstra A, Yang P. Molecular genetic advances in uveitis. Progress in Molecular Biology and Translational Science. 2015;134:283–298.
   PubMed Web of Science ®Google Scholar
• Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Survey of Ophthalmology. Jul-Aug 2005;50(4):297–350.
   PubMed Web of Science ®Google Scholar
• Alabdulaaly A, Rifkind J, Solow H, Messner HA, Lipton JH. Rescue of interferon induced bone marrow aplasia in a patient with chronic myeloid leukemia by allogeneic bone marrow transplant. Leukemia & Lymphoma. Jan 2004;45(1):175–177.
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Kirn E, Krueger GR, Fischer R. Bone marrow hypoplasia and fibrosis following interferon treatment. In Vivo. Jul-Aug 1994;8(4):605–612.
   PubMedGoogle Scholar
• Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. Feb 1986;4(2):234–243.
   PubMed Web of Science ®Google Scholar
• Perlemuter G, Bodaghi B, Le Hoang P, et al. Visual loss during interferon-alpha therapy in hepatitis C virus infection. Journal of Hepatology. Nov 2002;37(5):701–702.
   PubMed Web of Science ®Google Scholar
• Schulman JA, Liang C, Kooragayala LM, King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology. Feb 2003;110(2):437–442.
   PubMed Web of Science ®Google Scholar
• Lohmann CP, Kroher G, Bogenrieder T, Spiegel D, Preuner J. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. The Lancet. Apr 17, 1999;353(9161):1326.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Betterle C, Brollo L, et al. Autoantibodies during α-interferon therapy for chronic hepatitis B. Journal of Medical Virology. Jun 1991;34(2):132–135.
   PubMed Web of Science ®Google Scholar
• Wandl UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clinical Immunology and Immunopathology. Oct 1992;65(1):70–74.
   PubMedGoogle Scholar
• Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. European Journal of endocrinology/European Federation of Endocrine Societies. May 1995;132(5):587–593.
   PubMed Web of Science ®Google Scholar
• Brasnu E, Wechsler B, Bron A, et al. Efficacy of interferon-α for the treatment of Kaposi’s sarcoma herpesvirus-associated uveitis. American Journal of Ophthalmology. Oct 2005;140(4):746–748.
   PubMed Web of Science ®Google Scholar
• Lesire V, Arsene S, Piquemal R, Renard JP. [Familial recurrent bilateral panuveitis: efficiency of alpha interferon]. La Revue De Medecine Interne/Fondee … Par La Societe Nationale Francaise De Medecine Interne.. Jul 2003;24(7):464–468.
   PubMed Web of Science ®Google Scholar
• Sobacı G, Bayraktar Z, Bayer A. ORIGINAL ARTICLE, interferon alpha-2A treatment for serpiginous choroiditis. Ocular Immunology and Inflammation. Feb 2005;13(1):59–66.
   PubMed Web of Science ®Google Scholar
• Treusch M, Stubiger N, Vonthein R, et al. Influence of interferon-alpha on lymphocyte subpopulations in Behcet’s disease. Advances in Experimental Medicine and Biology. 2003;528:533–535.
   PubMed Web of Science ®Google Scholar
• Treusch M, et al. Influence of human recombinant interferon- 2a (rhIFN- 2a) on altered lymphocyte subpopulations and monocytes in Behcet’s disease. Rheumatology. Oct 2004;43(10):1275–1282.
   PubMed Web of Science ®Google Scholar
• Emmi L, Brugnolo F, Salvati G, Marchione T. Immunopathological aspects of Behcet’s disease. Clinical and Experimental Rheumatology. Nov-Dec 1995;13(6):687–691.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2016: behcet’s syndrome. Clinical and Experimental Rheumatology. Sep-Oct 2016;34(6 Suppl 102):10–22.
   PubMed Web of Science ®Google Scholar
• Du L, Kijlstra A, Yang P. Immune response genes in uveitis. Ocular Immunology and Inflammation. Jul-Aug 2009;17(4):249–256.
   PubMed Web of Science ®Google Scholar